NeuroMetrix Wearable Tech for Chemotherapy Pain Designated a Breakthrough Device

The FDA has granted NeuroMetrix’s Quell technology for chemotherapy pain a Breakthrough Device designation.

Quell is intended to reduce moderate-to-severe symptoms of chemotherapy-induced peripheral neuropathy that have persisted for at least six months following chemotherapy. The wearable neuromodulator uses position and motion sensing to automatically adjust stimulation.

The Quell device uses Bluetooth to communicate with smartphone and smartwatch apps that allow patients to personalize their treatment.

Chemotherapy-induced peripheral neuropathy occurs in many patients treated with common chemotherapeutic drugs, such as vincristine, paclitaxel and cisplatin. Symptoms include burning/shooting pain, tingling, cramping, and numbness in the hands and feet.